SecBot SecBot

VNRX

VOLITIONRX LTD
NYSE· In Vitro & In Vivo Diagnostic Substances· Inc. DE· CIK 0000093314 Biotech & Drug Discovery
$0.1900 +0.01 (+5.56%)
Oct 27 4:00 PM ET · prev $0.1800
Market cap
$5.2M
Nano cap
Median target
$20.00
+10426% · range $2.00–24.00
Next earnings
Nov 12
in 15 days · EPS est. −$0.31
1 year
−97.7%
from $8.40 · Oct 28
30 days
−24.0%
from $0.2500
52-week range
$0.1700–9.00
−98% from high · low Oct 19
Avg volume 20D
1.51M
Oct 1 spike 8.13M
Short interest
1.15M
≈3.8% of shares · −4.3%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
Filing reports
20
analyzed by SecBot
SecBot read BEARISH 9 reports · 90 days
Balance 7 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 7/9 ·Next Earnings date, Nov 12, 2026
Strongest BEARISH VolitionRx issued 2,157,340 shares to Lind Global Asset Management XII LLC via two debt conversions totaling…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.700 → −$0.310 over 90 days.

  • Short sellersSTEADY

    Short interest −4.3% to 1.15M shares. 1.0 days to cover, ≈3.8% of shares.

  • TrendDOWNTREND

    34% below its 50-day average. New closing low $0.1700 on Oct 23.

Who's buying

13F
Top holderSharesValue
GEODE CAPITAL MANAGEMENT, LLC55,537$75.0K
VANGUARD CAPITAL MANAGEMENT LLC50,684$68.4K
Wealthspire Advisors, LLC45,000$60.8K
STATE STREET CORP33,995$45.9K
VANGUARD FIDUCIARY TRUST CO25,133$33.9K
BlackRock, Inc.22,308$30.1K
NORTHERN TRUST CORP12,978$17.5K
Squarepoint Ops LLC10,685$14.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Apr 2026
12-month targets · 5 analysts

Price is below the lowest target. Median implies +10426%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Apr 20, 2026D. Boral Capital
DOWNGRADE
DOWNGRADEHold
Apr 2, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Mar 31, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Mar 26, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Mar 18, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Jan 21, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 21, 2026
Batchelor Ann-Louise
Group Chief Marketing Officer
AWARD12,000 sh
Sep 28, 2026
Forterre Gael
Chief Commercial Officer
TAX W/H$71.82
Sep 28, 2026
Michel Gaetan
Chief Operating Officer
TAX W/H$153.76

Earnings setup

Estimates
Nov 12
reports in 15 days
−$0.31
EPS estimate, this quarter
+56%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.31-$0.31–-$0.31+46.6%$696.1K
Next Q-$0.29-$0.29–-$0.29+40.8%$710.0K
Current FY-$2.00-$2.00–-$2.00+23.7%$2.7M
Next FY-$0.85-$0.85–-$0.85+26.1%$9.3M

Short side

FINRA· Oct 15, 2026
1,145,766
shares short
-4.3%
vs prior settlement
1.0
days to cover
≈3.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 21, 2026 Insider
Batchelor Ann-Louise was granted 12,000 shares
Group Chief Marketing Officer
Sep 28, 2026 Insider
Forterre Gael surrendered for taxes 284 shares
Chief Commercial Officer @ $0.2529 ($71.82)
Sep 28, 2026 Insider
Michel Gaetan surrendered for taxes 608 shares
Chief Operating Officer @ $0.2529 ($153.76)
Sep 25, 2026 SEC
VolitionRx issued 2,157,340 shares to Lind Global Asset Management XII LLC via two debt conversions totaling $525,000…
8-K — Impact 7/10
Sep 16, 2026 SEC
Lagoda Investment Management filed an amended Schedule 13D for VolitionRx, reporting a 5.9% stake (1,650,505 shares)…
SC 13D/A — Impact 3/10
Sep 15, 2026 Short interest report
Short Interest: VNRX down 55% to 1.0M shares
Settlement 2026-09-15 | Days to cover: 1.00 | ≈3.60% of shares outstanding (est.)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
VNRX Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Sep 15, 2026
Short interest
Short Interest: VNRX down 55% to 1.0M shares
Settlement 2026-09-15 | Days to cover: 1.00 | ≈3.60% of shares outstanding (est.)
Aug 31, 2026
Short interest
Short Interest: VNRX up 225% to 2.2M shares
Settlement 2026-08-31 | Days to cover: 1.00 | ≈11.88% of shares outstanding (est.)
Aug 19, 2026
Earnings date
VNRX Q2 2026 Earnings Scheduled — 2026-08-19
Aug 14, 2026
Earnings date
VNRX Q2 2026 Earnings Scheduled — 2026-08-14
May 13, 2026
Earnings date
VNRX Q1 2026 Earnings Scheduled — 2026-05-13

SecBot reports

20 filings · 0 bullish · 13 bearish · 1 mixed · 6 neutral
All VNRX filing & press-release reports (20)